Baker Bros. Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Baker Bros. Advisors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,732,502	Closed	-$254M	–	128
2022 Q3	$254M	Hold	3,732,502	–	–	1.66%	7
2022 Q2	$119M	Buy	3,732,502 +417,737	+13%	+$12.2M	0.68%	10
2022 Q1	$115M	Hold	3,314,765	–	–	0.66%	12
2021 Q4	$97M	Buy	3,314,765 +97,324	+3%	+$3.01M	0.47%	18
2021 Q3	$82M	Hold	3,217,441	–	–	0.36%	23
2021 Q2	$113M	Hold	3,217,441	–	–	0.49%	19
2021 Q1	$131M	Buy	3,217,441 +2,297,066	+250%	+$106M	0.57%	17
2020 Q4	$39.9M	Hold	920,375	–	–	0.15%	41
2020 Q3	$50.7M	Buy	920,375 +873,375	+1,858%	+$55.5M	0.2%	31
2020 Q2	$2.97M	Hold	47,000	–	–	0.01%	91
2020 Q1	$2.4M	Buy	+47,000	New	+$3.15M	0.01%	86
2016 Q2	–	Sell	-600,000	Closed	-$9.52M	–	141
2016 Q1	$9.52M	Buy	600,000 +200,000	+50%	+$3.55M	0.1%	57
2015 Q4	$12.9M	Buy	400,000 +200,000	+100%	+$8.66M	0.11%	58
2015 Q3	$8.43M	Buy	+200,000	New	+$9.44M	0.08%	66

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Baker Bros. Advisors's GBT Position: Q4 2022 in Review

Baker Bros. Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 3,732,502 shares — an estimated $254M sold.

Baker Bros. Advisors first reported a position in GBT in Q3 2015 and held it in 14 quarters. The position peaked at $254M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Baker Bros. Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Baker Bros. Advisors sold 3,732,502 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $254M.
Baker Bros. Advisors first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 14 quarters.
Baker Bros. Advisors's Global Blood Therapeutics, Inc. position peaked at $254M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.